CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Burst Diagnostics›
Analysis
Burst Diagnostics logo

Burst Diagnostics

Burst Diagnostics: Innovating rapid, at-home diagnostic solutions with our automated lab-in-hand platform.

Fort Collins, CO, US🇺🇸
Founded
2020
Loading
Overview
Analysis
Compare
Fundraising
Employees
Library

Contents

  1. 01Competitive Strengths
  2. 02Risk Factors
  3. 03Products & Services
  1. 01Competitive Strengths
  2. 02Risk Factors
  3. 03Products & Services

Competitive Advantages

Burst's defensible advantage is network access rather than a proven cost, data, distribution, or regulatory position. In 2026, Larry Jia, CEO of Zymo Research, and Tim Jones, COO of Innosphere Ventures, sit on Burst's board of directors, and both firms are early investors in the company.

Against named alternatives, cost and data advantages lack dated support, since no price, unit cost, or dataset size is disclosed for 2026. The only dated investor-side fact is the $2.44 million round dated 3 January 2024, which funds development rather than proving the sensitivity claim.

Source: burst-dx.com

Risk Factors

The most company-specific risk is financing: a $2.69 million capital base across four rounds, the latest dated January 2024, is small relative to the validation and manufacturing work a diagnostic cartridge requires, so further rounds are a dependency for the thesis.

The warning signs are a latest dated round more than two years old by 2026 and no named regulatory clearance for CaDI, and neither is offset by a disclosed revenue base that would fund the gap.

Source: burst-dx.com

Product Overview

Burst Diagnostics is positioned as a point-of-need quantitative testing platform rather than a laboratory instrument vendor, and its CaDI cartridge is the product that carries that position. In 2026, the cartridge returns quantitative immunoassay results in about 10 minutes and serves two buyers: consumers seeking at-home hormone insight and partners commissioning custom assays for other industries.

That split between a consumer test and a B2B assay service is the decisive packaging choice, and the partner side carries more of the company's commercial weight. Against rapid tests sold by other vendors, the offering competes on quantitative accuracy from a single cartridge rather than on price, since its stated advantage is lab-level sensitivity at the point of need.

Source: burst-dx.com